Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland

Emerg Infect Dis. 2020 Oct;26(10):2370-2377. doi: 10.3201/eid2610.190804.

Abstract

Public health authorities in the United States and Europe recommend surveillance for Clostridioides difficile infections among hospitalized patients, but differing diagnostic algorithms can hamper comparisons between institutions and countries. We compared surveillance based on detection of C. difficile by PCR or enzyme immunoassay (EIA) in a nationwide C. difficile prevalence study in Switzerland. We included all routinely collected stool samples from hospitalized patients with diarrhea in 76 hospitals in Switzerland on 2 days, 1 in winter and 1 in summer, in 2015. EIA C. difficile detection rates were 6.4 cases/10,000 patient bed-days in winter and 5.7 cases/10,000 patient bed-days in summer. PCR detection rates were 11.4 cases/10,000 patient bed-days in winter and 7.1 cases/10,000 patient bed-days in summer. We found PCR used alone increased reported C. difficile prevalence rates by <80% compared with a 2-stage EIA-based algorithm.

Keywords: Clostridioides difficile; Switzerland; antimicrobial resistance; bacteria; diagnosis; enteric infections; healthcare-associated infections; molecular assay; surveillance; toxin assay.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Toxins* / genetics
  • Clostridioides
  • Clostridioides difficile* / genetics
  • Clostridium Infections* / diagnosis
  • Clostridium Infections* / epidemiology
  • Cross-Sectional Studies
  • Europe
  • Feces
  • Humans
  • Prevalence
  • Switzerland / epidemiology

Substances

  • Bacterial Toxins